Kirin Holdings Company, Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNBWY research report →
Price Chart
About the company
Kirin Holdings Company, Limited, a diversified global conglomerate, was established in 1885 and maintains its headquarters in Tokyo, Japan. This entity operates across Japan and internationally, manufacturing and marketing a broad array of products. Its core activities are structured around four key divisions: Japan Beer and Spirits, Japan Non-Alcoholic Beverages, Oceania Integrated Beverages, and Pharmaceuticals.
- CEO
- Yoshinori Isozaki
- IPO
- 1980
- Employees
- 31,144
- HQ
- Tokyo, TY, JP
Get TickerSpark's AI analysis on KNBWY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.49B
- P/E
- 13.19
- Fwd P/E
- 0.09
- PEG
- 0.10
- P/S
- 0.99
- P/B
- 1.87
- EV/EBITDA
- 8.19
- Div Yield
- 2.38%
- Gross Margin
- 48.52%
- Op Margin
- 11.17%
- Net Margin
- 7.60%
- ROE
- 14.49%
- ROIC
- 8.04%
Latest fiscal year · YoY change
- Revenue
- $2.55T+9.1%
- Gross Profit
- $1.21T+13.9%
- Op Income
- $263.99B
- Net Income
- $154.69B+165.7%
- EPS
- $191.36+166.3%
- OCF Growth
- +27.6%
- FCF Growth
- +101.8%
- 52W High
- $20.21
- 52W Low
- $14.66
- 50D MA
- $18.53
- 200D MA
- $17.51
- Beta
- 0.04
- RSI (14)
- 51
- Avg Volume
- 24.33K
No earnings-call transcripts are available for KNBWY yet.
- Free Float
- 99.2%
- Shares Outstanding
- 796.74M
- Float Shares
- 790.27M
of shares held by institutions
1 13F filers
Congressional trading
Senate and House stock disclosures for KNBWY, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Held by 1 ETFs
Biggest fund positions in KNBWY by dollar value.
Our KNBWY coverage
Recent articles, reports, and earnings notes.
No research on KNBWY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KNBWY report →Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
globenewswire.com · Nov 4
Kirin (KNBWY) is an Incredible Growth Stock: 3 Reasons Why
zacks.com · Oct 21
Are Investors Undervaluing Kirin (KNBWY) Right Now?
zacks.com · Oct 21
Arcadia Biosciences (NASDAQ:RKDA) and Kirin (OTCMKTS:KNBWY) Financial Survey
defenseworld.net · Sep 2
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
globenewswire.com · Jun 23
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
globenewswire.com · Jun 11
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
globenewswire.com · Jun 10
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
globenewswire.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.